LifeSci Capital Reiterates Buy Rating on Veradermics, Inc.
LifeSci Capital maintains a buy rating on Veradermics, setting a $135 price target, a 31.34% upside from the current price.
Key Points
- LifeSci Capital reiterated its buy rating on Veradermics, Inc. (NYSE:MANE) with a price target of $135 on June 16, 2026.
- LifeSci Capital's $135 price target implies 31.34% upside from Veradermics, Incorporated's ($MANE) current $102.79 share price.
- Veradermics shares traded at $96.27, with a market cap of about $3.8 billion and a 52-week high of $117.71.
- Investment firms like Ameriprise Financial and Jennison Associates have significant stakes in Veradermics.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
LifeSci Capital has reiterated its buy rating on Veradermics, Incorporated (NYSE:MANE) with a price target of $135. This reaffirmation by analyst Rami Katkhuda was announced on June 16, 2026. Veradermics shares are currently trading at $96.27.
Other Institutional Activity in Veradermics
Several investment firms have shown interest in Veradermics. Ameriprise Financial Inc has established a position with 514,035 shares valued at approximately $32.5 million. Jennison Associates LLC holds 141,781 shares worth about $8.95 million. Emerald Advisers, LLC has 132,536 shares valued at around $8.37 million, while Emerald Mutual Fund Advisers Trust owns 109,283 shares worth approximately $6.9 million. Seven Grand Managers, LLC and Bamco Inc /NY/ also hold significant stakes.
Veradermics, Incorporated Stock Up 5.0%
Shares of Veradermics, Inc. (NYSE:MANE) are trading at $96.27. The company has a market capitalization of approximately $3.8 billion. Its stock has traded between a 52-week low of $32.00 and a high of $117.71. Veradermics has a forward P/E ratio that is not meaningful as the company is not currently profitable. The company's 50-day moving average is $92.38, while the 200-day moving average is $73.62. It boasts a robust current ratio of 59.12 and a quick ratio of 58.44, indicating strong liquidity.
Analysts Set New Price Targets
On June 16, 2026, LifeSci Capital reiterated its buy rating on Veradermics, setting a price target of $135. Earlier, Needham initiated coverage with a buy rating and a $136 target on June 2, 2026. Citigroup maintained its buy rating with a $135 target on May 18, 2026. The consensus among analysts is a strong buy, with an average price target of $132.25 based on four analyst opinions.
About Veradermics, Inc.
Veradermics, Incorporated is a biopharmaceutical company based in New Haven, Connecticut. Founded in 2019, it focuses on developing innovative treatments for dermatologic and aesthetic conditions. The company is working on therapies for pattern hair loss, alopecia areata, and other skin conditions. Its product portfolio includes VDPHL01 for hair loss and VDMN for common warts. Dr. Reid Waldman M.D. serves as the CEO.
Bottom Line
LifeSci Capital's reiterated buy rating and $135 price target highlight confidence in Veradermics' potential. Investors track such ratings for insights into a company's growth prospects. However, it's important to remember that analyst ratings are based on current data and projections, which can change over time.
Get Veradermics, Incorporated alerts
New 13F filings, insider trades, and analyst moves on $MANE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.